Impact of mitral regurgitation in patients with worsening heart failure: Insights from BIOSTAT-CHF
Matteo Pagnesi,Marianna Adamo,Iziah E Sama,Stefan D. Anker,John G.F. Cleland,John G.F. Cleland,Kenneth Dickstein,Kenneth Dickstein,Gerasimos Filippatos,Chim C. Lang,Leong L. Ng,Leong L. Ng,Piotr Ponikowski,Alice Ravera,Nilesh J. Samani,Nilesh J. Samani,Faiez Zannad,Dirk J. van Veldhuisen,Adriaan A. Voors,Marco Metra +19 more
TLDR
The role of mitral regurgitation in the BIOlogy Study to TAilored Treatment in chronic heart failure (BIOSTAT-CHF) was investigated in this paper.Abstract:
Background Few data regarding the prevalence and prognostic impact of mitral regurgitation (MR) in patients with worsening chronic or new-onset acute heart failure (HF) are available. We investigated the role of MR in the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF). Methods and results We performed a retrospective post-hoc analysis including patients from both the index and validation BIOSTAT-CHF cohorts with data regarding MR status. The primary endpoint was a composite of all-cause death or HF hospitalization. Among 4023 patients included, 1653 patients (41.1%) had moderate-severe MR. Compared to others, patients with moderate-severe MR were more likely to have atrial fibrillation and chronic kidney disease and had larger left ventricular (LV) dimensions, lower left ventricular ejection fraction (LVEF), worse QoL, and higher plasma concentrations of NT-proBNP. A primary outcome event occurred in 697 patients with, compared to 836 patients without, moderate-severe MR (Kaplan-Meier 2-year estimate: 42.2% vs. 35.3%; hazard ratio [HR], 1.28; 95% confidence interval [CI], 1.16-1.41; log-rank p Conclusions Moderate-severe MR is common in patients with worsening chronic or new-onset acute HF and is strongly associated with outcome, independently of other features related to HF severity. This article is protected by copyright. All rights reserved.read more
Citations
More filters
Journal ArticleDOI
Heart failure: an update from the last years and a look at the near future
M. Riccardi,Antonio Sammartino,Massimo F Piepoli,Marianna Adamo,Matteo Pagnesi,Giuseppe M.C. Rosano,Marco Metra,Stephan von Haehling,Daniela Tomasoni +8 more
TL;DR: In this paper , the authors present evidence for treatment of patients with mildly reduced or preserved ejection fraction (DELIVER) by using intravenous acetazolamide to loop diuretics, which leads to greater decongestion vs. placebo.
Journal ArticleDOI
Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure
Matteo Pagnesi,Marianna Adamo,Iziah E Sama,Stefan D. Anker,John G.F. Cleland,Kenneth Dickstein,Gerasimos Filippatos,Riccardo M. Inciardi,Chim C. Lang,Carlo Lombardi,Leong L. Ng,Piotr Ponikowski,Nilesh J. Samani,Faiez Zannad,Dirk J. van Veldhuisen,Adriaan A. Voors,Marco Metra +16 more
TL;DR: In this paper , the authors evaluated the evolution and impact of mitral regurgitation (MR) severity with guideline-recommended medical therapy (GRMT) in heart failure (HF).
Journal ArticleDOI
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
Riccardo M. Inciardi,Matteo Pagnesi,Carlo Lombardi,Stefan D. Anker,John G.F. Cleland,Kenneth Dickstein,Gerasimos Filippatos,Chim C. Lang,Leong L. Ng,Pierpaolo Pellicori,Piotr Ponikowski,Nilesh J. Samani,Faiez Zannad,Dirk J. van Veldhuisen,Scott D. Solomon,Adriaan A. Voors,Marco Metra +16 more
TL;DR: Changes in LA dimension may be a useful marker of response to treatment and improve risk stratification in patients with HF and was associated with an unfavourable outcome and was prevented by ACEi/ARBs uptitration.
References
More filters
Journal ArticleDOI
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski,Adriaan A. Voors,Stefan D. Anker,Héctor Bueno,John G.F. Cleland,Andrew J.S. Coats,Volkmar Falk,José Ramón González-Juanatey,Veli-Pekka Harjola,Ewa A. Jankowska,Mariell Jessup,Cecilia Linde,Petros Nihoyannopoulos,John Parissis,Burkert Pieske,Jillian P. Riley,Giuseppe M.C. Rosano,Luis M. Ruilope,Frank Ruschitzka,Frans H. Rutten,Peter van der Meer,Gerasimos Filippatos,John J.V. McMurray,Victor Aboyans,Stephan Achenbach,Stefan Agewall,Nawwar Al-Attar,John Atherton,Johann Bauersachs,A. John Camm,Scipione Carerj,Claudio Ceconi,Antonio Coca,Perry M. Elliott,Çetin Erol,Justin A. Ezekowitz,Covadonga Fernández-Golfín,Donna Fitzsimons,Marco Guazzi,Maxime Guenoun,Gerd Hasenfuss,Gerhard Hindricks,Arno W. Hoes,Bernard Iung,Tiny Jaarsma,Paulus Kirchhof,Juhani Knuuti,Philippe Kolh,Stavros Konstantinides,Mitja Lainscak,Patrizio Lancellotti,Gregory Y.H. Lip,Francesco Maisano,Christian Mueller,Mark C. Petrie,Massimo F Piepoli,Silvia G. Priori,Adam Torbicki,Hiroyuki Tsutsui,Dirk J. van Veldhuisen,Stephan Windecker,Clyde W. Yancy,José Luis Zamorano +62 more
TL;DR: Authors/Task Force Members: Piotr Ponikowski* (Chairperson) (Poland), Adriaan A. Voors* (Co-Chair person) (The Netherlands), Stefan D. Anker (Germany), Héctor Bueno (Spain), John G. F. Cleland (UK), Andrew J. S. Coats (UK)
Journal ArticleDOI
Transcatheter Mitral-Valve Repair in Patients with Heart Failure.
Gregg W. Stone,JoAnn Lindenfeld,William T. Abraham,Saibal Kar,D. Scott Lim,Jacob M. Mishell,Brian Whisenant,Paul A. Grayburn,Michael Rinaldi,Samir R. Kapadia,Vivek Rajagopal,Ian J. Sarembock,Andreas Brieke,Steven O. Marx,David J. Cohen,Neil J. Weissman,Michael J. Mack +16 more
TL;DR: Among patients with heart failure and moderate‐to‐severe or severe secondary mitral regurgitation who remained symptomatic despite the use of maximal doses of guideline‐directed medical therapy, transcatheter mitral‐valve repair resulted in a lower rate of hospitalization forHeart failure and lower all‐cause mortality within 24 months of follow‐up than medical therapy alone.
Journal ArticleDOI
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.
John G.F. Cleland,Karl Swedberg,Ferenc Follath,Michel Komajda,Alain Cohen-Solal,J.C. Aguilar,Rainer Dietz,Antonello Gavazzi,R. Hobbs,Jerzy Korewicki,Hugo Madeira,V. S. Moiseyev,István Préda,W. H. Van Gilst,J Widimsky,Nick Freemantle,Joanne Eastaugh,James Mason +17 more
TL;DR: Most men but a minority of women who underwent investigation of cardiac function had evidence of moderate or severe left ventricular dysfunction, the main target of current advances in the treatment of heart failure.
Journal ArticleDOI
Ischemic Mitral Regurgitation Long-Term Outcome and Prognostic Implications With Quantitative Doppler Assessment
TL;DR: Patients with previous (>16 days) Q-wave MI by ECG who underwent transthoracic echocardiography found that after 5 years, total mortality and cardiac mortality for patients with IMR were higher than for those without IMR.
Journal ArticleDOI
Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging
Patrizio Lancellotti,Christophe Tribouilloy,Andreas Hagendorff,Bogdan A. Popescu,Thor Edvardsen,Thor Edvardsen,Luc Pierard,Luigi P. Badano,José Luis Zamorano +8 more
TL;DR: It is crucial to provide standards that aim at establishing a baseline list of measurements to be performed when assessing regurgitation, and to integrate the quantification of the regurgitations, assessment of the valve anatomy and function, as well as the consequences of valvular disease on cardiac chambers.